The ethics of placebo-controlled trials - A middle ground

New England Journal of Medicine

Volumn 345, Issue 12, 2001, Pages 915-919

  Emanuel, Ezekiel J ^a   Miller, Franklin G ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; METOCLOPRAMIDE; NEW DRUG; ONDANSETRON; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; INFORMED CONSENT; MEDICAL ETHICS; MORBIDITY; PATIENT RIGHT; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; WELLBEING;

ANALYTICAL APPROACH; BIOMEDICAL AND BEHAVIORAL RESEARCH; CLINICAL APPROACH/SOURCE;

ANGINA PECTORIS; CONTROLLED CLINICAL TRIALS; ETHICS, MEDICAL; HUMANS; PLACEBOS;

EID: 0035922438     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200109203451211     Document Type: Review

References (42)

1. The Fielding H. Garrison Lecture: Ceteris paribus: The evolution of the clinical trial
2. A study of the placebo response
3. Placebos and controlled trials under attack
4. Should placebo-controlled trials be abolished?
5. Placebo controls
6. Government viewpoint of clinical trials
7. Problems in interpreting active control equivalence trials
8. Placebo-controlled trials and active-control trials in the evaluation of new treatments. I. Ethical and scientific issues
9. Placebo-controlled trials and active-control trials in the evaluation of new treatments. II. Practical issues and specific cases
10. Placebo orthodoxy in clinical research. I. Empirical and methodological myths
11. Placebo orthodoxy in clinical research. II. Ethical, legal, and regulatory myths
12. Placebo-controlled trials and the logic of clinical purpose
13. The continuing unethical use of placebo controls
14. Declaration of Helsinki should be strengthened
15. Ethical issues in the design and conduct of clinical trials in developing countries
16. Research involving human subjects in developing countries
17. Helsinki's new clinical rules: Fewer placebos, more disclosure
18. Active control equivalence studies
19. Antiemetic efficacy of high-dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting
20. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting
21. The delayed-emesis syndrome from cisplatin: Phase III evaluation of ondansetron versus placebo
22. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy
23. Onadansetron and cisplatin-induced nausea and vomiting
24. What makes clinical research ethical?
25. 3 (serotonin) antagonist ondansetron (GR 38032F) with highdose metoclopramide in the control of cisplatin-induced emesis
26. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy
27. The ethical design of human experiments
28. The misunderstood placebo
29. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: An analysis of the Food and Drug Administration database
30. The placebo effect in cardiovascular disease
31. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment
32. Placebo-controlled trials in psychiatric research: An ethical perspective
33. Placebo protects subjects from nonresponse: A paradox of power
34. When are placebo-controlled trials no longer appropriate?
35. Helsinki discord? A controversial declaration
36. Evaluation of internal mammary artery ligation and sham procedure in angina pectoris
37. An evaluation of internal-mammary-artery ligation by a double-blind technic
38. Chelation therapy for intermittent claudication: A double-blind, randomised, controlled trial
39. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
40. Placebo study questions effectiveness of laser heart treatment
41. Exposing patients with chronic, stable, exertional angina to placebo periods in drug trials